NCLH vs PRLD · P/E 16, rev $4.97B vs rev $10.3M
Norwegian Cruise Line Holdings Ltd (NCLH) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Latest reported PRLD revenue for 2026-06-30 was $10.3M. Net income was -$24.3M. PRLD currently screens at market cap $346.5M.
NCLH currently screens at market cap $9.10B and trailing P/E 16.0. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the NCLH and PRLD stock pages for the full models.
Not investment advice.